RE: Allometric scaling of renal clearance with estimated glomerular filtration rate
Dear Nick, Hans, Ruben, Max,
Great to hear several approaches and opinions on the use of glomerular
filtration approximations in PK modeling and scaling to body size. Thank you!
I have a hard time ignoring the CKD-EPI equations (with or without cystatin C),
as they are well established and proven better predictors for GFR, when
compared to the Cockroft-Gault. In general, sample sizes of pharmacokinetic
studies are smaller than those where the CKD-EPI and MDRD equations were
developed. I am not convinced that developing a new creatinine/cystatin c
equation for GFR for each PK analysis is the right approach. Then again, I also
have a hard time scaling to BSA, as in, for example, obese patients this is
likely a poor body size descriptor to scale renal function.
Also, depending on the population and drug one may choose one equation above
another. For example: if a drug is completely filtrated (no active secretion),
a cystatin C based equation is likely better explain variability in clearance
of completely filtrated drugs (e.g. carboplatin). Another example: in cachectic
patients one may argue that there is not enough muscle mass (and thus serum
creatinine) to provide accurate GFR estimations and then creatinine-independent
equations may provide better equations.
Thinking about this the last couple of days and with your feedback, I am
inclined to choose the equation based on population (e.g. cachectic or not?)
and drug (e.g. filtration/active secretion) and, if the equation scales renal
function to BSA, convert it to scaling to FFM. Nonetheless, open to any other
suggestion or discuss cons and pro's anytime!
Sincerely,
Rob
-----Oorspronkelijk bericht-----
Quoted reply history
Van: [email protected] [mailto:[email protected]] Namens
Nick Holford
Verzonden: woensdag 6 december 2017 20:06
Aan: [email protected]
Onderwerp: Re: [FORGED] [NMusers] Allometric scaling of renal clearance with
estimated glomerular filtration rate
Hi Rob,
Thanks for bringing this up again. I don't think much has changed since I wrote
this in 2013
( http://cognigencorp.com/nonmem/current/2013-August/4697.html)
1. Theory Based Allometry or Surface Area
"Note that using surface area as a form of size standardization forglomerular
filtration rate has no theoretical nor experimental support when compared to
theory based allometry (Rhodin et al. 2009). So I donot agree with
standardizing CLCR to 1.73 m^2. I know this is frequently done but in fact this
is just based on tradition and an out of datetheory of scaling based on surface
area (see Anderson & Holford 2008)."
There is no biological or experimental support for using surface area to scale
renal function markers such as GFR and CLcr. In contrast, there is strong
biological based theory and experimental support for using theory based
allometry (see Holford & Anderson 2017 for a recent review).
2. Mechanism Based Models for CLcr
I also wrote in 2013:
"The MDRD method of predicting glomerular filtration rate is astatistical
absurdity which does not include any measurement of size for its prediction. I
would certainly not recommend using it for anyscientific purpose. "
This applies equally well to the CKD-EPI method. Let me explain why it is a
absurdity generated by a naive statistician using CLcr as an example.
CLcr can be calculated from the creatinine excretion rate (CER) and the serum
creatiniine. This is based on the definition of clearance and is true without
any assumptions.
CLcr=CER/Scr
If we then assume Scr is at steady state then CER will be equal to creatinine
production rate (CPR) and we can use this:
CLcr=CPR/Scr
All rational models for predicting CLcr without measurement of CER use models
to predict CPR e.g.
CPR=(140-Age)*Weight/72 use Cockcroft & Gault to predict CPR in males then
CLcr=CPR/Scr is Cockcroft & Gault CLcr ml/min
Dividing CPR by Scr gives the CLcr. This can be written equivalently but less
clearly:
CLcr=CPR*Scr^-1
The empirical models such as MDRD and CKI-EPI (see below) involve the absurdity
of estimating the known exponent for Scr of -1. These estimates must be wrong
based on the theory I have outlined above (unless the estimate is exactly -1).
The reported estimates are -1.209 for CKI-EPI and -1.154 for MDRD.
In addition, and more importantly,they have no direct measure of body size
which seriously limits the value outside the typical weight distribution and
they are only applicable to adults. GFR can be described from premature
neonates to adults using theory based allometry and maturation based on
post-menstrual age so GFR predicttions should try to follow the concepts used
there (Rhodin 2008).
So what to do?
First -- don't use MDRD or CKI-EPI unless you are sure you are applying them to
a population similar to that used to develop these empirical predictions. You
could add allometric scaling to the eGFR by assuming the 1.72m^2 value is
equivalent to 70 kg with a fat free mass (FFM) of
56.1 kg. Then scaling the eGFR by (WT/70)^(3/4) or (FFM/56.1)^(3/4).
I use the Schwartz (1992) equations for neonates, children and teenagers then
the Matthews (2004) equation for adults. I am working on an integrated method
for CPR prediction which was presented as a work in progress at PAGE this year.
Watch this space...
Best wishes,
Nick
MDRD
eGFR =175 x (SCr)^-1.154 x (age)-0.203 x 0.742 [if female] x
1.212 [if Black]
CKI-EPI
eGFR = 141 x min(SCr/k, 1)^alpha x max(SCr /kappa, 1)^-1.209 x 0.993^Age
x 1.018 [if female] x 1.159 [if Black]
kappa = 0.7 (females) or 0.9 (males)
alpha = -0.329 (females) or -0.411 (males)
eGFR (estimated glomerular filtration rate) = mL/min/1.73 m2; SCr (standardized
serum creatinine) = mg/dL
Holford NHG, Anderson BJ. Allometric size: The scientific theory and
extension to normal fat mass. Eur J Pharm Sci. 2017;109(Supplement):S59-S64.
Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M,
Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH
Human renal function maturation – a quantitative description using
weight and postmenstrual age. Pediatr Nephrol. 2008
Schwartz GJ. Does kL/PCr estimate GFR, or does GFR determine k? Pediatr
Nephrol. 1992;6(6):512-5.
Matthews I, Kirkpatrick C, Holford N. Quantitative justification for
target concentration intervention -- parameter variability and
predictive performance using population pharmacokinetic models for
aminoglycosides. Br J Clin Pharmacol. 2004;58(1):8-19.
Holford N, Sherwin CM. Scaling renal function in neonates and infants to
describe the pharmacodynamics of antibiotic nephrotoxicity. PAGE 26
Abstr 7208 [wwwpage-meetingorg/?abstract=7208]. 2017.
On 06-Dec-17 23:52, [email protected] wrote:
>
> Hi Ruben,
>
> Interesting work, Ruben. One may indeed question the validity of
> glomerular filtration rate markers like cystatin C (that is only
> filtrated and not actively secreted) to predict PK of drugs that
> undergo active tubular secretion in patients with decreased renal
> function. When glomerular filtration rate drops, the relative
> contribution of active tubular secretion to renal clearance increases.
> To me, it appears logical that creatinine is a better marker for
> clearance drugs that are actively secreted, as creatinine also
> undergoes active tubular secretion.
>
> Nonetheless, I’m also interested whether other people have considered
> allometric scaling of MDRD/CKD-EPI derived GFR’s?
>
> Cheers,
>
> Rob
>
> *Van: *Ruben Faelens <[email protected]>
> *Datum: *dinsdag 5 december 2017 om 7:13 PM
> *Aan: *"Heine, Rob ter" <[email protected]>
> *CC: *"[email protected]" <[email protected]>
> *Onderwerp: *Re: [NMusers] Allometric scaling of renal clearance with
> estimated glomerular filtration rate
>
> Dear Rob,
>
> At PMX Benelux, there was an interesting talk about the correlation
> between different metrics describing renal function by Stijn Jonckheere.
> A part of the work presented was published:
> https://academic.oup.com/jac/article/71/9/2538/1750427
> https://academic.oup.com/jac/article/71/9/2538/1750427
>
> This may provide some perspective, or rather complicate things even
> more, depending on your viewpoint.
>
> Best regards
> Ruben Faelens
>
On 06-Dec-17 06:17, [email protected] wrote:
>
> Dear all,
>
> I am wondering what your thoughts are on the allometric scaling of
> clearance of renally extreted drugs, where we have estimations renal
> function.
>
> Simply scaling the predicted glomerular filtration rate from, for
> example, the Cockroft-gault equation seems inappropriate, since weight
> is already a part of the equation. Standardizing this to weight in the
> Cockroft-gault equation can be done, a solution has been discussed
> here: http://cognigencorp.com/nonmem/current/2013-August/4697.html
>
> However, in the recent years some new equations to calculate
> glomerular filtration rate from endogenous markers have emerged. For
> example the CKD-EPI CREATININE CYSTATIN C equation
> https://www.kidney.org/content/ckd-epi-creatinine-cystatin-equation-2012
> . As the addition of a muscle mass independent endogenous marker like
> cystatin C is known to provide better estimations of GFR in, for
> example, cachectic patients, it is likely that this equation may
> outperform to predict renally filtrated compounds in this patient
> group. It is rather odd that this CKD-EPI equation does not contain
> any measure of body size. The outcome of this equation is a GFR scaled
> to a BSA of 1.73m^2.
>
> I am wondering how you would allometrically scale the eGFRs from these
> CKD EPI equations to, for example, fat-free mass.
>
> Cheers!
>
> Rob
>
> R. ter Heine, PhD, PharmD
>
> Hospital Pharmacist-Clinical Pharmacologist
>
> Radboudumc, Nijmegen, The Netherlands
>
> Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het
> handelsregister onder nummer 41055629.
> The Radboud university medical center is listed in the Commercial
> Register of the Chamber of Commerce under file number 41055629.
>
--
Nick Holford, Professor Clinical Pharmacology
Dept Pharmacology & Clinical Pharmacology, Bldg 503 Room 302A
University of Auckland,85 Park Rd,Private Bag 92019,Auckland,New Zealand
office:+64(9)923-6730 mobile:NZ+64(21)46 23 53 FR+33(6)62 32 46 72
email:[email protected]
http://holford.fmhs.auckland.ac.nz/
http://orcid.org/0000-0002-4031-2514
Read the question, answer the question, attempt all questions
Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het
handelsregister onder nummer 41055629.
The Radboud university medical center is listed in the Commercial Register of
the Chamber of Commerce under file number 41055629.